Management of cough in lung cancer

Download Report

Transcript Management of cough in lung cancer

Management of cough
in lung cancer
Clinical guidelines for the management of
cough in lung cancer:
report of a UK Task Group on Cough.
Molassiotis A1, Smith JA2, Bennett MI3, Blackhall
F4, Taylor D5, Zavery B6, Harle A4, Booton R7,
Rankin EM8, Lloyd-Williams M9, Morice AH10.
Epidemiology
• Cough is common symptom
– 23-37% of all cancer patients
– 47-86% in lung cancer
• Not always well managed
• Little evidence to guide practice
• Formation of task group
• Literature reviews
• Peer review by UK committees
• Submitted for publication
Pathophysiology
• Coughing serves to protect airway from
irritants
• Stimuli provoke cough via vagus nerve
through
– chemoreceptors (C fibres)
– mechanoreceptors (A delta fibres)
In lung cancer
• Ulceration of mucosa
– Mechanical stimulation
• Release of inflammatory mediators
– Chemoreceptor stimulation
– Sensitises peripheral nerves
• Also:
–
–
–
–
–
Obstruction
Pleural effusion
Infection
Fistulas
Carcinomatosis
Recommendations
Assessment
• History
– Type of cough (productive / non-productive)
– Trigger factors
– Nocturnal or day time
• Co-morbid conditions
– COPD
– Heat failure
• No validated symptom scale available
Assessment
• Drugs causing cough
– Methotrexate
– Bleomycin
– ACE inhibitors
• Further investigations
– ?CXR
– CT
Treat reversible causes
• COPD / asthma
– Inhaled bronchodilators
– Steroid (prednisolone 30mg daily)
• Infection (bronchietctasis, LRTI)
– antibiotics
• GI reflux
– PPI (omeprazole)
– Metoclopramide or domperidone for non-acid reflux-
Treat the cancer
• Chemo
– Improves symptoms including cough
• External radiotherapy
• Brachytherapy
Symptomatic management
• Linctus
– Glycerol
– Simple linctus
• Trial of steroid
– Prednisolone
– (or dexamethasone)
Centrally acting agents
• Codeine
– 30mg qds
• Morphine or methadone
– If codeine no help
– Morphine 5-10mg bd
• No dose response relationship for cough
Peripherally acting agents
• Antitussive agents
– Levodropropizine,
– Moguisteine
– Levocloperastine
• Local anaesthetic agents
– nebulised bupivacaine
– benzonatate
In general
• Low levels of evidence for these
recommendations
• Peripheral and intermittent approaches
before central and continuous treatment
• In lung cancer
– many patients already on opioids for pain
• Central approaches maximised already
EXPERIMENTAL
Carbamazepine,
Thalidomide, Gabapentin,
Baclofen Amitriptylline
LOCAL ANAESTHETICS
Nebulised Lidocaine
Benzonatate
PERIPHERALLY-ACTING ANTITUSSIVES
Levodropropizine, Moguisteine, Levocloperastine
OPIOIDS
Morphine/Methadone
Dextromethorphan, Codeine, Hydrocodone
CONSIDER ORAL STEROID TRIAL
2 weeks
CANCER SPECIFIC
systemic chemotherapy/RT endobronchial
therapy, PDT, palliative RT
CO-MORBIDITIES
COPD, reflux, asthma, infections